BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 25803498)

  • 1. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
    Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pathological analyses of transplant glomerulopathy cases.
    Shimizu T; Ishida H; Toki D; Nozaki T; Omoto K; Tanabe K; Honda K; Koike J
    Nephrology (Carlton); 2014 Jun; 19 Suppl 3():21-6. PubMed ID: 24842817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
    Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
    Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
    Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.
    Gupta G; Abu Jawdeh BG; Racusen LC; Bhasin B; Arend LJ; Trollinger B; Kraus E; Rabb H; Zachary AA; Montgomery RA; Alachkar N
    Transplantation; 2014 Jun; 97(12):1240-6. PubMed ID: 24937198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection.
    Matignon M; Muthukumar T; Seshan SV; Suthanthiran M; Hartono C
    Transplantation; 2012 Sep; 94(6):603-11. PubMed ID: 22932115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
    Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
    Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Antibody-Mediated Rejection in Kidney Transplant Based on the 2013 Banff Criteria: Single-Center Experience in Uruguay.
    Nin M; Coitiño R; Kurdian M; Orihuela L; Astesiano R; Garau M; López D; Rievas G; Rodriguez I; González-Martínez F; Noboa O
    Transplant Proc; 2016 Mar; 48(2):612-5. PubMed ID: 27110014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical and molecular significance of C4d staining patterns in renal allografts.
    Hayde N; Bao Y; Pullman J; Ye B; Calder BR; Chung M; Schwartz D; Alansari A; de Boccardo G; Ling M; Akalin E
    Transplantation; 2013 Feb; 95(4):580-8. PubMed ID: 23274969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification.
    Mauiyyedi S; Crespo M; Collins AB; Schneeberger EE; Pascual MA; Saidman SL; Tolkoff-Rubin NE; Williams WW; Delmonico FL; Cosimi AB; Colvin RB
    J Am Soc Nephrol; 2002 Mar; 13(3):779-787. PubMed ID: 11856785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Relationship of the Severity and Category of Acute Rejection With Intimal Arteritis Defined in Banff Classification to Clinical Outcomes.
    Wu K; Budde K; Schmidt D; Neumayer HH; Rudolph B
    Transplantation; 2015 Aug; 99(8):e105-14. PubMed ID: 25719260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.
    Eskandary F; Bond G; Schwaiger E; Kikic Z; Winzer C; Wahrmann M; Marinova L; Haslacher H; Regele H; Oberbauer R; Böhmig GA
    Trials; 2014 Apr; 15():107. PubMed ID: 24708575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of C4d staining with minimal histologic abnormalities.
    Haas M
    Curr Opin Organ Transplant; 2010 Feb; 15(1):21-7. PubMed ID: 19907328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute T cell-mediated rejection accompanied by C4d-negative acute antibody-mediated rejection and cell debris in tubulus: A case report.
    Takamura T; Yamamoto I; Nakada Y; Katsumata H; Yamakawa T; Furuya M; Mafune A; Kobayashi A; Tanno Y; Miki J; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():70-4. PubMed ID: 26031591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal allograft biopsies in the era of C4d staining: the need for change in the Banff classification system.
    Al-Aly Z; Reddivari V; Moiz A; Balasubramanian G; Cortese CM; Salinas-Madrigal L; Bastani B
    Transpl Int; 2008 Mar; 21(3):268-75. PubMed ID: 18069927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
    Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
    Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
    Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
    Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probable C4d-negative accelerated acute antibody-mediated rejection due to non-HLA antibodies.
    Niikura T; Yamamoto I; Nakada Y; Kamejima S; Katsumata H; Yamakawa T; Furuya M; Mafune A; Kobayashi A; Tanno Y; Miki J; Yamada H; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():75-8. PubMed ID: 26031592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation.
    Immenschuh S; Zilian E; Dämmrich ME; Schwarz A; Gwinner W; Becker JU; Blume CA
    Transplantation; 2015 Jan; 99(1):56-62. PubMed ID: 25121474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology of C4d-negative antibody-mediated rejection in renal allografts.
    Haas M
    Curr Opin Organ Transplant; 2013 Jun; 18(3):319-26. PubMed ID: 23283250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.